Converge Bio Secures $25M Series A to Advance AI-Driven Drug Discovery
Converge Bio, an AI-powered drug discovery startup, has raised $25 million in a Series A funding round led by Bessemer Venture Partners, with additional investments from executives at Meta, OpenAI, and Wiz. This capital injection aims to accelerate the development of innovative therapies using artificial intelligence.
